Literature DB >> 28130232

ANAQUIN: a software toolkit for the analysis of spike-in controls for next generation sequencing.

Ted Wong1, Ira W Deveson1,2, Simon A Hardwick1,3, Tim R Mercer1,3.   

Abstract

SUMMARY: Spike-in controls are synthetic nucleic-acid sequences that are added to a user's sample and constitute internal standards for subsequent steps in the next generation sequencing workflow.
AVAILABILITY AND IMPLEMENTATION: : The software is implemented in C ++/R and is freely available under BSD license. The source code is available from github.com/student-t/Anaquin , binaries and user manual from www.sequin.xyz/software and R package from bioconductor.org/packages/Anaquin. CONTACT: anaquin@garvan.org.au or t.mercer@garvan.org.au. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com

Entities:  

Mesh:

Year:  2017        PMID: 28130232     DOI: 10.1093/bioinformatics/btx038

Source DB:  PubMed          Journal:  Bioinformatics        ISSN: 1367-4803            Impact factor:   6.937


  8 in total

1.  Reduced nuclear NAD+ drives DNA damage and subsequent immune activation in the retina.

Authors:  Emily E Brown; Michael J Scandura; Sudeep Mehrotra; Yekai Wang; Jianhai Du; Eric A Pierce
Journal:  Hum Mol Genet       Date:  2022-05-04       Impact factor: 5.121

2.  A combined RNA-seq and whole genome sequencing approach for identification of non-coding pathogenic variants in single families.

Authors:  Revital Bronstein; Elizabeth E Capowski; Sudeep Mehrotra; Alex D Jansen; Daniel Navarro-Gomez; Mathew Maher; Emily Place; Riccardo Sangermano; Kinga M Bujakowska; David M Gamm; Eric A Pierce
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

3.  YAP1 Mediates Resistance to MEK1/2 Inhibition in Neuroblastomas with Hyperactivated RAS Signaling.

Authors:  Grace E Coggins; Alvin Farrel; Komal S Rathi; Colin M Hayes; Laura Scolaro; Jo Lynne Rokita; John M Maris
Journal:  Cancer Res       Date:  2019-10-31       Impact factor: 12.701

4.  Correction of amyotrophic lateral sclerosis related phenotypes in induced pluripotent stem cell-derived motor neurons carrying a hexanucleotide expansion mutation in C9orf72 by CRISPR/Cas9 genome editing using homology-directed repair.

Authors:  Nidaa A Ababneh; Jakub Scaber; Rowan Flynn; Andrew Douglas; Paola Barbagallo; Ana Candalija; Martin R Turner; David Sims; Ruxandra Dafinca; Sally A Cowley; Kevin Talbot
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

5.  Chiral DNA sequences as commutable controls for clinical genomics.

Authors:  Ira W Deveson; Bindu Swapna Madala; James Blackburn; Chris Barker; Ted Wong; Kirston M Barton; Martin A Smith; D Neil Watkins; Tim R Mercer
Journal:  Nat Commun       Date:  2019-03-22       Impact factor: 14.919

6.  Long read sequencing reveals novel isoforms and insights into splicing regulation during cell state changes.

Authors:  David J Wright; Nicola A L Hall; Naomi Irish; Angela L Man; Will Glynn; Arne Mould; Alejandro De Los Angeles; Emily Angiolini; David Swarbreck; Karim Gharbi; Elizabeth M Tunbridge; Wilfried Haerty
Journal:  BMC Genomics       Date:  2022-01-10       Impact factor: 3.969

7.  Using synthetic chromosome controls to evaluate the sequencing of difficult regions within the human genome.

Authors:  Andre L M Reis; Ira W Deveson; Bindu Swapna Madala; Ted Wong; Chris Barker; Joshua Xu; Niall Lennon; Weida Tong; Tim R Mercer
Journal:  Genome Biol       Date:  2022-01-12       Impact factor: 13.583

8.  Synthetic microbe communities provide internal reference standards for metagenome sequencing and analysis.

Authors:  Simon A Hardwick; Wendy Y Chen; Ted Wong; Bindu S Kanakamedala; Ira W Deveson; Sarah E Ongley; Nadia S Santini; Esteban Marcellin; Martin A Smith; Lars K Nielsen; Catherine E Lovelock; Brett A Neilan; Tim R Mercer
Journal:  Nat Commun       Date:  2018-08-06       Impact factor: 14.919

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.